Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 437-450-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 18 August 2000 to 07 May 2001.
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 001
- Report date:
- 2001
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Deviations:
- not specified
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- yes
Test material
- Reference substance name:
- -
- EC Number:
- 437-450-6
- EC Name:
- -
- Cas Number:
- 64654-05-3
- Molecular formula:
- Hill formula: C28 H37 N
- IUPAC Name:
- N-(dodecylphenyl)naphthalen-1-amine
- Test material form:
- liquid: viscous
- Details on test material:
- Sponsor's identification: APAN
Description: redbrown viscous liquid
Lot number: EL01010B01/KZ8911.5
Storage conditions: room temperature in the dark
1
- Specific details on test material used for the study:
- No further details specified in the study report.
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- The rat was selected for this study as it is a readily available rodent species historically used in safety evaluation studies and is acceptable to appropriate regulatory authorities.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- A sufficient number of male and female Sprague-Dawley Crl:CD (SD) IGS BR strain rats were obtained from Charles River (UK) Limited, Margate, Kent. On receipt the animals were examined for signs of ill-health or injury. The animals were acclimatised for eight days during which time their health status was assessed. A total of forty animals (twenty males and twenty females) were accepted into the study. At the start of treatment the males weighed 127 to 169g, and the females weighed 1 16 to 158g and were approximately five to seven weeks old.
The animals were housed in groups of five by sex in polypropylene grid-floor cages suspended over trays lined with absorbent paper. The animals were allowed free access to food and water. A pelleted diet (Rat and Mouse SQC Expanded Diet No. 1, Special Diets Services Limited, Witham, Essex, UK) was used. Mains drinking water was supplied from polycarbonate bottles attached to the cage. The diet and drinking water were considered not to contain any contaminant at a level that might have affected the purpose of integrity of the study. Environmental enrichment was provided in the form of wooden chew blocks (B & K Universal Ltd., Hull, UK).
The animals were housed in a single air-conditioned room within the Safepharm Barrier Maintained Rodent Facility. The rate of air exchange was at least fifteen air changes per hour and the low intensity fluorescent lighting was controlled to give twelve hours continuous light and twelve hours darkness. Environmental conditions were continuously monitored by a computerised system, and print-outs of hourly mean temperatures and humidities were included in the study records. The temperature and relative humidity were controlled to remain within target ranges of 21 ± 2 °C and 55 ± 15% respectively. On one occasion the relative humidity was outside the respective target but was considered not to have affected the purpose or integrity of the study.
The animals were randomly allocated to treatment groups using random letter tables and the group mean bodyweights were then determined to ensure similarity between the treatment groups. The cage distribution within the holding rack was also randomised. The animals were uniquely identified within the study by an ear punching system routinely used in these laboratories.
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- The test material was administered daily, for twenty-eight consecutive days, by gavage using a stainless steel cannula attached to a disposable plastic syringe. Control animals were treated in an identical manner with 2 ml/kg/day of Arachis oil BP.
- Vehicle:
- arachis oil
- Details on oral exposure:
- For the purpose of this study the test material was prepared at the appropriate concentrations as a solution in Arachis oil BP.
Formulations were prepared weekly and stored at approximately +4 °C in the dark. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Summary
The concentration of APAN in the test material formulations was determined by high performance liquid chromatography (HPLC) using an external standard technique.
Samples
The test material formulations were extracted with acetonitrile to give a final, theoretical test material concentration of approximately 0.1 mg/ml.
Standards
Standard solutions of test material were prepared in acetonitrile at a nominal concentration of 0.1 mg/ml.
Procedure
The standard and sample solutions were analysed by HPLC using the following conditions:
GC system: Hewlett-Packard 1050, incorporating autosampler and workstation
Column: Luna C18(250 x 4.6 mm id)
Mobile phase: acetonitrile:water (70:30 v/v)
Flow rate: 1.0 ml/min
UV detector wavelength: 217 nm
Injection volume: 10 μl
Retention time: ~ 13 mins
Homogeneity Determinations
The test material formulations were mixed thoroughly and samples were taken from the top, middle and bottom of the container, shaking in between sampling. Sampling was performed in triplicate.
Stability Determinations
The test material formulations were sampled and analysed initially and then after storage at approximately +4 °C in the dark for fourteen days.
Verification of Test Material Formulation Concentrations
The test material formulations were sampled and analysed within three days of preparation.
Linearity
A range of standard solutions were prepared covering the concentration range 0 to 0.2 mg/ml and analysed.
The detector response was shown to be linear up to 0.2 mg/ml.
Specificity
The diluent solvent acetonitrile and a blank Arachis oil BP(control) were analysed.
Analysis of the solvent and a blank Arachis oil BP (control) produced no signal that interfered with the signal due to the test material. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 15 mg/kg bw/day (nominal)
- Dose / conc.:
- 150 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10 animals per dose (5 male/5 female)
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- The dose levels were chosen based on the results of the range-finding study. The oral route was selected as the most appropriate route of exposure, based on the physical properties of the test material, and the results of the study are believed to be of value in predicting the likely toxicity of the test material to man.
- Positive control:
- Not required for this study.
Examinations
- Observations and examinations performed and frequency:
- Clinical Observations
All animals were examined for overt signs of toxicity, ill-health or behavioural change immediately before dosing and one and five hours after dosing during the working week. Animals were observed immediately before dosing and one hour after dosing at weekends. All observations were recorded.
Functional Observations
Prior to the start of treatment and on Days 5, 13, 19 and 26 all animals were observed for signs of functional/behavioural toxicity. Functional performance tests were also performed on all animals during the final week of the study, together with an assessment of sensory reactivity to different stimuli. Observations were carried out from approximately two hours after dosing on each occasion.
Behavioural Assessments
Detailed individual clinical observations were performed for each animal using a purpose built arena. The following parameters were observed:
Gait; Tremors; Twitches; Convulsions; Bizarre/Abnormal/Stereotypic behaviour; Salivation; Pilo-erection; Exophthalmia; Lachrymation; Hyper/Hypothermia; Skin colour; Respiration; Palpebral closure; Urination; Defecation; Transfer arousal; Tail elevation
Functional Performance Tests
Motor Activity: Twenty purpose built 44 infra-red beam automated activity monitors were used to assess motor activity. Animals of one sex were tested at each occasion and were randomly allocated to the activity monitors. The tests were performed at approximately the same time each day, under similar laboratory conditions. The evaluation period was sixteen hours for each animal. The percentage of time each animal was active and mobile was recorded for the overall sixteen hour period and also during the final 20% of the period (considered to be the asymptotic period).
Forelimb/hindlimb Grip Strength: An automated grip strength meter was used. Each animal was allowed to grip the proximal metal bar of the meter with its forepaws. The animal was pulled by the base of the tail until its grip was broken. The animal was drawn along the trough of the meter by the tail until its hind paws gripped the distal metal bar. The animal was pulled by the base of the tail until its grip was broken. A record of the force required to break the grip for each animal was made. Three consecutive trials were performed for each animal.
Sensory Reactivity
Each animal was individually assessed for sensory reactivity to auditory, visual and proprioceptive stimuli. The following parameters were observed:
Grasp response; Vocalisation; Toe pinch; Tail pinch; Finger approach; Touch escape; Pupil reflex; Startle reflex; Blink reflex
Bodyweight
Individual bodyweights were recorded on Day 0 (the day before the start of treatment) and on Days 7, 14, 21 and 28. Bodyweights were also recorded at terminal kill.
Food Consumption
Food consumption was recorded for each cage group at weekly intervals throughout the study.
Water Consumption
Water intake was observed daily, for each cage group, by visual inspection of the water bottles for any overt changes.
Laboratory Investigations
Haematological and blood chemical investigations were performed on all animals from each test and control group at the end of the study (Day 28). Blood samples were obtained from the lateral tail vein. Where necessary repeat samples were obtained by cardiac puncture prior to necropsy on Day 29. Animals were not fasted prior to sampling.
Haematology
The following parameters were measured on blood collected into tubes containing potassium EDTA anti-coagulant:
Haemoglobin (Hb)
Erythrocyte count (RBC)
Haematocrit (Hct)
Erythrocyte indices: mean corpuscular haemoglobin (MCH); mean corpuscular volume (MCV); mean corpuscular haemoglobin concentration (MCHC)
Total leucocyte count (WBC)
Differential leucocyte count: neutrophils (Neut); lymphocytes (Lymph); monocytes (Mono); eosinophils (Eos); basophils (Bas)
Platelet count (PLT)
Reticulocyte count (Retic): Cresyl blue stained slides were prepared but reticulocytes were not assessed
Prothrombin time (CT) was assessed by 'Hepato Quick' and Activated partial thromboplastin time (APTT) was assessed by 'Preci Clot' using samples collected into sodium citrate solution (0.11 mol/l).
Blood Chemistry
The following parameters were measured on plasma from blood collected into tubes containing lithium heparin anti-coagulant:
Urea; Glucose; Total protein (Tot.Prot.); Albumin; Albumin/Globulin (AIG) ratio (by calculation); Sodium (Na+); Potassium (K+); Chloride (Cl-); Calcium (Ca++); Inorganic phosophorus (P); Aspartate aminotransferase (ASAT); Alanine aminotransferase (ALAT); Alkaline phosphatase (AP); Creatinine (Creat); Total cholesterol (Chol); Total bilirubin (Bili). - Sacrifice and pathology:
- Pathology
On completion of the dosing period all animals were killed by intravenous overdose of sodium pentobarbitone (Sagatal, 60 mglml; Rhone MCrieux, Dagenharn, Essex, UK) followed by exsanguination.
All animals were subjected to a full external and internal examination, and any macroscopic abnormalities were recorded.
Organ Weights
The following organs, removed from animals that were killed at the end of the study, were dissected free from fat and weighed before fixation:
Adrenals; Brain; Epididymides; Heart; Kidneys; Liver; Ovaries; Spleen; Testes; Thymus
Histopathology
Samples of the following tissues were removed from all animals and preserved in buffered 10% formalin:
Adrenals; Aorta (thoracic); Bone & bone marrow (femur including stifle joint); Bone & bone marrow (sternum); Brain (including cerebrum, cerebellum and pons); Caecum; Colon; Duodenum; Epididymides; Eyes; Gross lesions; Heart; Ileum; Oesophagus; Ovaries; Pancreas; Pituitary; Prostate; Rectum; Salivary glands (submaxillary); Sciatic nerve; Seminal vesicles; Skin (hind limb); Spinal cord (cervical); Spleen; Stomach; Jejunum; Kidneys; Liver; Lungs (with bronchi); Lymph nodes (cervical and mesenteric); Muscle (skeletal); Testes; Thymus; Thyroid/parathyroid; Trachea; Urinary bladder; Uterus
All tissues were despatched Precision Histology International, One Eyed Lane, Weybread, Diss,
Norfolk, UK for processing. The tissues from all control and 1000 mg/kg/day dose group animals were prepared as paraffin blocks, sectioned at nominal thickness of 5 pm and stained with haematoxylin and eosin for subsequent microscopic examination. The liver and spleen from all 15 and 150 mg/kg/day dose group animals were also processed.
Since there were indications of treatment-related hepatic changes, examination was subsequently extended to include similarly prepared sections of liver from all animals in the other treatment groups. - Other examinations:
- Not further examinations specified in the study report.
- Statistics:
- Data were processed to give group mean values and standard deviations where appropriate.
Haematological, blood chemical, organ weight (absolute and relative to terminal bodyweight), weekly bodyweight gain and quantitative functional performance and sensory reactivity data were assessed for dose response relationships by linear regression analysis followed by one way analysis of variance (ANOVA) incorporating Levene's test for homogeneity of variance. Where variances were shown to be homogenous painvise comparisons were conducted using Dunnett's test. Where Levene's test showed unequal variances the data were analysed using non-parametric methods: Kruskal-Wallis ANOVA and Mann-Whitney 'U' test.
The haematology variable basophils was not analysed since consistently greater than 30% of the data were recorded as the same value.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Increased salivation was detected immediately before or up to ten minutes after dosing for animals of either sex treated with 1000 mg/kg/day from Day 4 onwards. Females from this treatment group developed hunched posture from Day 9 together with isolated incidents of prolonged increased salivation or fur staining. Pink staining on the cage tray-liners was detected for animals of either sex treated with 1000 or 150 mg/kg/day throughout the treatment period but this was probably normal excretion of the test material or its metabolite(s).
No treatment-related effects were detected at 15 mg/kg/day. - Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- A statistically significant reduction in bodyweight gain was detected for females treated with 1000 mg/kg/day during the first two weeks of the study. Females treated with 150 mg/kg/day also showed a slight reduction in bodyweight gain but this was confined to Week 2 only.
No adverse effect on bodyweight development was detected for the male treatment groups or for females treated with 15 mg/kg/day. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- A reduction in dietary intake and food efficiency was detected for females treated with 1000 mg/kg/day during the first two weeks of the study. Food efficiency was slightly reduced for 150 mg/kg/day females but this was confined to Week 2 only.
No such effects were detected for the male treatment groups or for animals of either sex treated with 15 mg/kg/day. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Slight reductions in haemoglobin, erythrocyte count and haematocrit were detected for animals of either sex at 1000 mg/kg/day but statistical significance was not achieved.
No such effects were detected for animals of either sex treated with 150 or 15 mg/kg/day. - Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Animals of either sex from all treatment groups showed an increase in plasma bilirubin, increasing in a dose-related response.
No other treatment-related effects were detected. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- Open-field assessment confirmed the clinical sign of hunched posture seen in 1000 mg/kg/day females from Week 2 onwards and increased salivation was detected in one male during Week 4.
No treatment-related effects were detected for animals of either sex treated with 150 or 15 mg/kg/day. - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Animals of either sex treated with 1000 mg/kg/day showed a statistically significant increase in liver weight, relative to bodyweight, compared with controls. Relative liver weight was also elevated for animals of either sex treated with 150 mg/kg/day but statistical significance was not achieved. Females treated with 1000 mg/kg/day showed an elevated relative spleen weight whilst absolute and relative adrenal weight was increased for this sex at both 1000 and 150 mg/kg/day.
No treatment-related organ weight changes were detected at 15 mg/kg/day. - Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Histopathological evaluation revealed treatment-related liver changes.
Centrilobular hepatocyte enlargement was observed in relation to treatment for animals of either sex treated with 1000 or 150 mg/kg/day, the effect extending to three 15 mg/kg/day males.
Hepatocyte enlargement is commonly observed in the rodent liver following the administration of xenobiotics and, in the absence of associated inflammatory or degenerative changes, it is generally considered to be adaptive in nature. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Details on results:
- The administration of APAN by oral gavage for a period of up to twenty-eight consecutive days resulted in treatment-related effects at dose levels of 1000, 150 and 15 mg/kg/day. Animals treated with 1000 mg/kg/day developed clinically observable signs during the study period involving increased salivation and hunched posture. Bodyweight development and dietary intake were adversely affected at this dose level during Weeks 1 and 2 but recovered over the final two weeks of treatment. A slight reduction in bodyweight and food efficiency was also detected at 150 mg/kg/day but this was confined to the females during Week 2 only. Haematological investigations revealed evidence of a mild anaemia in animals of either sex treated with 1000 mg/kg/day. A slight increase in relative spleen weight was also detected which probably indicates that a compensatory haemopoietic response has been initiated. In the absence of any histopathological correlates, the condition was considered to be minimal, representing a secondary response to treatment. Blood chemical investigations revealed a substantial increase in plasma bilirubin at all dose levels with many values outside normal ranges. This may have been associated with the anaemia present at the high dose but is more likely to be associated with liver change. Liver weights were elevated in animals of either sex treated with 1000 or 150 mg/kg/day and microscopic examination of liver sections revealed centrilobular hepatocyte enlargement at these dose levels and for three males treated with 15 mg/kg/day. Increased hepatic activity of this type is considered a normal adaptive biological response to xenobiotics and is usually the result of detoxification mechanisms involving hepatic enzyme induction. Nevertheless the unusually high levels of plasma bilirubin cannot be disregarded and, as such, a toxicologically significant liver effect is likely to have been demonstrated, albeit minimal at the lower dose levels.
The remaining organ weight changes detected were confined to a statistically significant increase in absolute and relative adrenal weight for 1000 and 150 mg/kg/day females. This increase may possibly have been a stress response associated with expansion of the adrenal cortex, but, in the absence of pathological changes, may be of no consequence.
Effect levels
open allclose all
- Key result
- Dose descriptor:
- other: EC50
- Effect level:
- 150 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- behaviour (functional findings)
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- haematology
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
- Key result
- Dose descriptor:
- NOAEL
- Remarks on result:
- not determinable
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Any other information on results incl. tables
Summary Incidence if Daily Clinical Observations – Males
Dose Level (mg/kg/day) |
Number of Animals |
Clinical Observations |
Number Showing Effects At Observation |
||||||||||||||||||||
Day: 1 |
Day: 2 |
Day: 3 |
Day: 4 |
Day: 5 |
Day: 6 |
Day: 7 |
|||||||||||||||||
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
|||
0 (Control) |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
15 |
5 |
Generalised fur loss No abnormalities detected |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
● ● |
0 5 |
0 5 |
● ● |
1 4 |
1 4 |
1 4 |
1 4 |
1 4 |
1 4 |
1 4 |
1 4 |
1 4 |
150 * |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
1000 #* |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
Dose Level (mg/kg/day) |
Number of Animals |
Clinical Observations |
Number Showing Effects At Observation |
||||||||||||||||||||
Day: 8 |
Day: 9 |
Day: 10 |
Day: 11 |
Day: 12 |
Day: 13 |
Day: 14 |
|||||||||||||||||
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
|||
0 (Control) |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
15 |
5 |
Generalised fur loss No abnormalities detected |
1 4 |
1 4 |
1 4 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
● ● |
0 5 |
0 5 |
● ● |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
150 * |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
1000 #* |
5 |
Increased salivation No abnormalities detected |
0 5 |
0 5 |
0 5 |
2 3 |
0 5 |
0 5 |
1 4 |
0 5 |
● ● |
1 4 |
0 5 |
● ● |
1 4 |
0 5 |
0 5 |
2 3 |
0 5 |
0 5 |
2 3 |
0 5 |
0 5 |
Dose Level (mg/kg/day) |
Number of Animals |
Clinical Observations |
Number Showing Effects At Observation |
||||||||||||||||||||
Day: 15 |
Day: 16 |
Day: 17 |
Day: 18 |
Day: 19 |
Day: 20 |
Day: 21 |
|||||||||||||||||
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
|||
0 (Control) |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
15 |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
150 * |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
1000 #* |
5 |
Increased salivation No abnormalities detected |
1 4 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
● ● |
0 5 |
0 5 |
● ● |
1 4 |
0 5 |
0 5 |
1 4 |
0 5 |
0 5 |
1 4 |
0 5 |
0 5 |
Dose Level (mg/kg/day) |
Number of Animals |
Clinical Observations |
Number Showing Effects At Observation |
||||||||||||||||||||
Day: 22 |
Day: 23 |
Day: 24 |
Day: 25 |
Day: 26 |
Day: 27 |
Day: 28 |
|||||||||||||||||
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
|||
0 (Control) |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
15 |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
150 * |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
1000 #* |
5 |
Increased salivation No abnormalities detected |
2 3 |
0 5 |
0 5 |
2 3 |
0 5 |
0 5 |
0 5 |
0 5 |
● ● |
0 5 |
0 5 |
● ● |
0 5 |
1 4 |
1 4 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
0 5 |
Pre = immediately before dosing
1h = one hour after dosing
5h = five hours after dosing
● = five hour observation not performed at weekend
# = increased salivation detected up to ten minutes after dosing – Days 4 to 28 inclusive
* = pink staining detected on cage tray-liners – Days 1 to 28 inclusive
Summary Incidence if Daily Clinical Observations – Females
Dose Level (mg/kg/day) |
Number of Animals |
Clinical Observations |
Number Showing Effects At Observation |
||||||||||||||||||||
Day: 1 |
Day: 2 |
Day: 3 |
Day: 4 |
Day: 5 |
Day: 6 |
Day: 7 |
|||||||||||||||||
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
|||
0 (Control) |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
15 |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
150 * |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
1000 #* |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
Dose Level (mg/kg/day) |
Number of Animals |
Clinical Observations |
Number Showing Effects At Observation |
||||||||||||||||||||
Day: 8 |
Day: 9 |
Day: 10 |
Day: 11 |
Day: 12 |
Day: 13 |
Day: 14 |
|||||||||||||||||
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
|||
0 (Control) |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
15 |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
150 * |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
1000 #* |
5 |
Hunched posture Increased salivation No abnormalities detected |
0 1 4 |
0 0 5 |
0 0 5 |
3 1 2 |
3 0 2 |
3 0 2 |
3 1 2 |
3 0 2 |
● ● ● |
4 2 1 |
4 0 1 |
● ● ● |
4 1 1 |
4 0 1 |
4 0 1 |
5 2 0 |
5 0 0 |
5 0 0 |
5 2 0 |
5 0 0 |
5 0 0 |
Dose Level (mg/kg/day) |
Number of Animals |
Clinical Observations |
Number Showing Effects At Observation |
||||||||||||||||||||
Day: 15 |
Day: 16 |
Day: 17 |
Day: 18 |
Day: 19 |
Day: 20 |
Day: 21 |
|||||||||||||||||
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
|||
0 (Control) |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
15 |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
150 * |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
1000 #* |
5 |
Hunched posture Increased salivation No abnormalities detected |
5 0 0 |
5 0 0 |
5 0 0 |
5 2 0 |
5 0 0 |
5 0 0 |
4 0 1 |
4 0 1 |
● ● ● |
4 0 1 |
4 0 1 |
● ● ● |
4 2 1 |
4 0 1 |
5 0 0 |
5 1 0 |
5 0 0 |
5 0 0 |
5 0 0 |
5 0 0 |
5 0 0 |
Dose Level (mg/kg/day) |
Number of Animals |
Clinical Observations |
Number Showing Effects At Observation |
||||||||||||||||||||
Day: 22 |
Day: 23 |
Day: 24 |
Day: 25 |
Day: 26 |
Day: 27 |
Day: 28 |
|||||||||||||||||
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
Pre |
1h |
5h |
|||
0 (Control) |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
15 |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
150 * |
5 |
No abnormalities detected |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
● |
5 |
5 |
● |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
1000 #* |
5 |
Hunched posture Increased salivation No abnormalities detected |
5 2 0 |
5 0 0 |
5 0 0 |
5 4 0 |
5 1 0 |
5 0 0 |
5 1 0 |
5 0 0 |
● ● ● |
5 0 0 |
5 0 0 |
● ● ● |
5 0 0 |
5 1 0 |
5 0 1 |
5 0 1 |
5 0 1 |
5 0 0 |
5 0 0 |
5 0 1 |
5 0 1 |
Pre = immediately before dosing
1h = one hour after dosing
5h = five hours after dosing
● = five hour observation not performed at weekend
# = increased salivation detected up to ten minutes after dosing – Days 4 to 28 inclusive
* = pink staining detected on cage tray-liners – Days 1 to 28 inclusive
Summary Incidence of Behavioural Assessments – Males
Pre-test
Dose Level (mg/kg/day) |
0 (Control) |
15 |
150 |
1000 |
||||||||
Number of Animals |
5 |
5 |
5 |
5 |
||||||||
Number Classified As Observation |
0 |
4 |
6 |
0 |
1 |
4 |
6 |
0 |
4 |
0 |
1 |
4 |
Urination |
5 |
0 |
0 |
4 |
1 |
0 |
0 |
5 |
0 |
3 |
2 |
0 |
Transfer arousal |
0 |
4 |
1 |
0 |
0 |
4 |
1 |
0 |
5 |
0 |
0 |
5 |
Week 1
Dose Level (mg/kg/day) |
0 (Control) |
15 |
150 |
1000 |
||||||
Number of Animals |
5 |
5 |
5 |
5 |
||||||
Number Classified As Observation |
0 |
4 |
0 |
1 |
4 |
0 |
4 |
0 |
1 |
4 |
Urination |
5 |
0 |
5 |
0 |
0 |
5 |
0 |
4 |
1 |
0 |
Defecation |
5 |
0 |
3 |
2 |
0 |
5 |
0 |
5 |
0 |
0 |
Transfer arousal |
0 |
5 |
0 |
0 |
5 |
0 |
5 |
0 |
0 |
5 |
Week 2
Dose Level (mg/kg/day) |
0 (Control) |
15 |
150 |
1000 |
|||||||
Number of Animals |
5 |
5 |
5 |
5 |
|||||||
Number Classified As Observation |
0 |
1 |
4 |
0 |
1 |
4 |
0 |
4 |
0 |
1 |
4 |
Urination |
4 |
1 |
0 |
4 |
1 |
0 |
5 |
0 |
4 |
1 |
0 |
Defecation |
5 |
0 |
0 |
4 |
1 |
0 |
5 |
0 |
5 |
0 |
0 |
Transfer arousal |
0 |
0 |
5 |
0 |
0 |
5 |
0 |
5 |
0 |
0 |
5 |
Week 3
Dose Level (mg/kg/day) |
0 (Control) |
15 |
150 |
1000 |
||||||||
Number of Animals |
5 |
5 |
5 |
5 |
||||||||
Number Classified As Observation |
0 |
1 |
4 |
0 |
1 |
4 |
0 |
1 |
4 |
0 |
1 |
4 |
Urination |
3 |
2 |
0 |
4 |
1 |
0 |
3 |
2 |
0 |
4 |
1 |
0 |
Defecation |
4 |
1 |
0 |
5 |
0 |
0 |
5 |
0 |
0 |
5 |
0 |
0 |
Transfer arousal |
0 |
0 |
5 |
0 |
0 |
5 |
0 |
0 |
5 |
0 |
0 |
5 |
Week 4
Dose Level (mg/kg/day) |
0 (Control) |
15 |
150 |
1000 |
||||||
Number of Animals |
5 |
5 |
5 |
5 |
||||||
Number Classified As Observation |
0 |
4 |
0 |
4 |
0 |
1 |
4 |
0 |
2 |
4 |
Salivation |
5 |
0 |
5 |
0 |
5 |
0 |
0 |
4 |
1 |
0 |
Urination |
5 |
0 |
5 |
0 |
4 |
1 |
0 |
5 |
0 |
0 |
Defecation |
5 |
0 |
5 |
0 |
4 |
1 |
0 |
5 |
0 |
0 |
Transfer arousal |
0 |
5 |
0 |
5 |
0 |
0 |
5 |
0 |
0 |
5 |
Summary Incidence of Behavioural Assessments – Females
Pre-test
Dose Level (mg/kg/day) |
0 (Control) |
15 |
150 |
1000 |
||||||||
Number of Animals |
5 |
5 |
5 |
5 |
||||||||
Number Classified As Observation |
0 |
4 |
6 |
0 |
1 |
4 |
6 |
0 |
4 |
0 |
1 |
4 |
Urination |
5 |
0 |
0 |
3 |
2 |
0 |
0 |
5 |
0 |
2 |
3 |
0 |
Transfer arousal |
0 |
3 |
2 |
0 |
0 |
4 |
1 |
0 |
5 |
0 |
0 |
5 |
Week 1
Dose Level (mg/kg/day) |
0 (Control) |
15 |
150 |
1000 |
||||
Number of Animals |
5 |
5 |
5 |
5 |
||||
Number Classified As Observation |
0 |
4 |
0 |
4 |
0 |
4 |
0 |
4 |
Transfer arousal |
0 |
5 |
0 |
5 |
0 |
5 |
0 |
5 |
Week 2
Dose Level (mg/kg/day) |
0 (Control) |
15 |
150 |
1000 |
|||||||
Number of Animals |
5 |
5 |
5 |
5 |
|||||||
Number Classified As Observation |
0 |
4 |
0 |
4 |
0 |
1 |
4 |
0 |
1 |
4 |
H |
Bizarre behaviour |
5 |
0 |
5 |
0 |
4 |
0 |
0 |
0 |
0 |
0 |
5 |
Urination |
5 |
0 |
5 |
0 |
5 |
0 |
0 |
4 |
1 |
0 |
0 |
Defecation |
5 |
0 |
5 |
0 |
4 |
1 |
0 |
5 |
0 |
0 |
0 |
Transfer arousal |
0 |
5 |
0 |
5 |
0 |
0 |
5 |
0 |
0 |
5 |
0 |
H = Hunched posture
Week 3
Dose Level (mg/kg/day) |
0 (Control) |
15 |
150 |
1000 |
||||||
Number of Animals |
5 |
5 |
5 |
5 |
||||||
Number Classified As Observation |
0 |
4 |
0 |
4 |
0 |
4 |
0 |
1 |
4 |
H |
Bizarre behaviour |
5 |
0 |
5 |
0 |
5 |
0 |
0 |
0 |
0 |
5 |
Urination |
5 |
0 |
5 |
0 |
5 |
0 |
5 |
0 |
0 |
0 |
Defecation |
5 |
0 |
5 |
0 |
5 |
0 |
4 |
1 |
0 |
0 |
Transfer arousal |
0 |
5 |
0 |
5 |
0 |
5 |
0 |
0 |
5 |
0 |
H = Hunched posture
Week 4
Dose Level (mg/kg/day) |
0 (Control) |
15 |
150 |
1000 |
|||||
Number of Animals |
5 |
5 |
5 |
5 |
|||||
Number Classified As Observation |
0 |
4 |
0 |
4 |
0 |
4 |
0 |
4 |
H |
Bizarre behaviour |
5 |
0 |
5 |
0 |
5 |
0 |
0 |
0 |
5 |
Transfer arousal |
0 |
5 |
0 |
5 |
0 |
5 |
0 |
5 |
0 |
H = Hunched posture
Group Mean Functional Performance Test Values and Standard Deviations (SD) - Males
Dose Level (mg/kg/day) |
Number of Animals |
|
Group Strength (g) |
Motor Activity |
||||
Overall |
Final 20% if Trail |
|||||||
Forelimb |
Hindlimb |
% Activity |
% Mobile Activity |
% Activity |
% Mobile Activity |
|||
0 (Control) |
5 |
mean sd |
755 249 |
340 84 |
28.3 5.6 |
5.0 1.0 |
15.9 8.0 |
1.9 0.8 |
15 |
5 |
mean sd |
707 188 |
339 83 |
27.0 4.2 |
5.1 0.3 |
9.5 3.2 |
1.2 0.6 |
150 |
5 |
mean sd |
700 160 |
318 85 |
25.6 3.1 |
4.5 0.6 |
14.5 2.6 |
2.0 0.5 |
1000 |
5 |
mean sd |
613 191 |
319 102 |
29.1 4.4 |
5.6 1.3 |
11.0 6.2 |
1.5 1.2 |
Group Mean Functional Performance Test Values and Standard Deviations (SD) - Females
Dose Level (mg/kg/day) |
Number of Animals |
|
Group Strength (g) |
Motor Activity |
||||
Overall |
Final 20% if Trail |
|||||||
Forelimb |
Hindlimb |
% Activity |
% Mobile Activity |
% Activity |
% Mobile Activity |
|||
0 (Control) |
5 |
mean sd |
659 169 |
282 63 |
26.2 5.3 |
5.5 0.9 |
12.3 6.1 |
2.3 1.1 |
15 |
5 |
mean sd |
757 192 |
320 80 |
33.7 9.2 |
7.1 2.4 |
14.4 9.4 |
3.0 2.9 |
150 |
5 |
mean sd |
682 172 |
281 70 |
29.0 4.3 |
6.2 1.7 |
11.0 4.7 |
2.1 1.6 |
1000 |
5 |
mean sd |
629 226 |
301 63 |
30.4 1.9 |
6.5 0.9 |
12.9 3.1 |
2.1 0.8 |
Sensory Reactivity Assessments – Males
Summary Incidence
Dose Level (mg/kg/day) |
0 (Control) |
15 |
150 |
1000 |
|||||||||||||
Number of Animals |
5 |
5 |
5 |
5 |
|||||||||||||
Number Classified As Observation |
0 |
1 |
2 |
4 |
6 |
0 |
2 |
4 |
6 |
0 |
2 |
4 |
6 |
0 |
2 |
4 |
6 |
Grasp response |
4 |
0 |
1 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
4 |
1 |
0 |
0 |
Vocalisation |
4 |
1 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
4 |
1 |
0 |
0 |
Toe pinch |
0 |
0 |
2 |
0 |
3 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
Tail pinch |
0 |
0 |
1 |
4 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
Finger approach |
0 |
0 |
5 |
0 |
0 |
0 |
4 |
0 |
1 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
Touch escape |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
Pupil reflex |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
Blink reflex |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
Sensory Reactivity Assessments – Females
Summary Incidence
Dose Level (mg/kg/day) |
0 (control) |
15 |
150 |
1000 |
||||||||||||||||
Number of Animals |
5 |
5 |
5 |
5 |
||||||||||||||||
Number Classified As Observation |
0 |
1 |
2 |
4 |
6 |
0 |
2 |
4 |
6 |
0 |
2 |
3 |
4 |
5 |
6 |
0 |
2 |
3 |
4 |
6 |
Grasp response |
2 |
0 |
3 |
0 |
0 |
2 |
3 |
0 |
0 |
3 |
1 |
0 |
0 |
0 |
1 |
4 |
1 |
0 |
0 |
0 |
Vocalisation |
1 |
2 |
1 |
1 |
0 |
2 |
3 |
0 |
0 |
3 |
0 |
1 |
0 |
1 |
0 |
4 |
0 |
1 |
0 |
0 |
Toe pinch |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
5 |
Tail pinch |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
0 |
5 |
0 |
Finger approach |
0 |
0 |
4 |
0 |
1 |
0 |
4 |
0 |
1 |
0 |
5 |
0 |
0 |
0 |
0 |
0 |
3 |
0 |
0 |
2 |
Touch escape |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
4 |
1 |
0 |
0 |
0 |
3 |
0 |
2 |
0 |
0 |
0 |
3 |
2 |
Pupil reflex |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
0 |
5 |
0 |
Blink reflex |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
0 |
5 |
0 |
Group Mean Weekly Bodyweights and Standard Deviations (SD) - Males
Dose Level (mg/kg/day) |
Number of Animals |
|
Bodyweight (g) at Day |
||||
0 |
7 |
14 |
21 |
28 |
|||
0 (Control) |
5 |
mean sd |
151 14 |
209 20 |
265 24 |
315 30 |
349 36 |
15 |
5 |
mean sd |
146 8 |
202 10 |
259 10 |
307 10 |
341 9 |
150 |
5 |
mean sd |
151 13 |
213 17 |
270 22 |
322 29 |
356 38 |
1000 |
5 |
mean sd |
153 16 |
209 19 |
260 22 |
308 22 |
337 22 |
Group Mean Weekly Bodyweights and Standard Deviations (SD) - Females
Dose Level (mg/kg/day) |
Number of Animals |
|
Bodyweight (g) at Day |
||||
0 |
7 |
14 |
21 |
28 |
|||
0 (Control) |
5 |
mean sd |
135 13 |
175 18 |
202 21 |
223 22 |
236 19 |
15 |
5 |
mean sd |
133 10 |
165 13 |
190 15 |
213 20 |
226 22 |
150 |
5 |
mean sd |
139 12 |
170 13 |
190 11 |
207 12 |
219 16 |
1000 |
5 |
mean sd |
137 12 |
163 7 |
177 5 |
193 6 |
205 7 |
Group Mean Weekly Bodyweight Gains and Standard Deviations (SD) - Males
Dose Level (mg/kg/day) |
Number of Animals |
|
Increase in Bodyweight (g) during Week |
|||
1 |
2 |
3 |
4 |
|||
0 (Control) |
5 |
mean sd |
58 8 |
56 8 |
50 9 |
34 8 |
15 |
5 |
mean sd |
56 3 |
57 4 |
48 4 |
34 6 |
150 |
5 |
mean sd |
63 5 |
57 7 |
52 8 |
34 12 |
1000 |
5 |
mean sd |
56 3 |
51 6 |
48 6 |
29 3 |
Group Mean Weekly Bodyweight Gains and Standard Deviations (SD) - Females
Dose Level (mg/kg/day) |
Number of Animals |
|
Increase in Bodyweight (g) during Week |
|||
1 |
2 |
3 |
4 |
|||
0 (Control) |
5 |
mean sd |
40 8 |
28 5 |
21 2 |
13 5 |
15 |
5 |
mean sd |
32 6 |
25 8 |
23 6 |
13 3 |
150 |
5 |
mean sd |
31 4 |
*20 4 |
17 3 |
12 4 |
1000 |
5 |
mean sd |
**25 6 |
**14 2 |
16 4 |
11 1 |
* significantly difference from control group p<0.05
** significantly different from control group p<0.01
Applicant's summary and conclusion
- Conclusions:
- Oral administration of the test material, APAN, to rats for a period of twenty-eight consecutive days at dose levels of up to 1000 mg/kg/day resulted in treatment-related effects at all dose levels.
A "No Observed Effect Level" (NOEL) has, therefore, not been achieved.
The treatment-related changes detected at 150 or 15 mg/kg/day were minimal and, in isolation, were considered not to represent serious damage to health, as defined by the criteria given in the EC labelling guide of Commission Directive 93/21/EEC. - Executive summary:
The study was designed to investigate the systemic toxicity of the test material. It complies with the requirements for notification of a new chemical substance in the EC and follows the testing method described in Commission Directive 96/54/EC (Method B7) and OECD Guidelines for Testing of Chemicals No. 407 "Repeated Dose 28 Day Oral Toxicity Study in Rodents" (Adopted 27 July 1995).
The test material was administered by gavage to three groups, each of five male and five female Sprague-Dawley Crl:CD (SD) IGS BR strain rats, for twenty-eight consecutive days, at dose levels of 15, 150 and 1000 mg/kg/day. A control group of five males and five females was dosed with vehicle alone (Arachis oil BP).
Clinical signs, functional observations, bodyweight development and food and water consumption were monitored during the study. Haematology and blood chemistry were evaluated for all animals at the end of the study.
All animals were subjected to gross necropsy examination and histopathological evaluation of selected tissues was performed.
Results.
Mortality: There were no deaths during the study.
Clinical Observations: Increased salivation was detected immediately before or up to ten minutes after dosing for animals of either sex treated with 1000 mg/kg/day from Day 4 onwards. Females from this treatment group developed hunched posture from Day 9 together with isolated incidents of prolonged increased salivation or fur staining. Pink staining on the cage tray-liners was detected for animals of either sex treated with 1000 or 150 mg/kg/day throughout the treatment period but this was probably normal excretion of the test material or its metabolite(s).
No treatment-related effects were detected at 15 mg/kg/day.
Behavioural Assessment: Open-field assessment confirmed the clinical sign of hunched posture seen in 1000 mg/kg/day females from Week 2 onwards and increased salivation was detected in one male during Week 4.
No treatment-related effects were detected for animals of either sex treated with 150 or 15 mg/kg/day.
Functional Performance Tests: No treatment-related effects were detected.
Sensory Reactivity Assessments: No treatment-related effects were detected.
Bodyweight: A statistically significant reduction in bodyweight gain was detected for females treated with 1000 mg/kg/day during the first two weeks of the study. Females treated with 150 mg/kg/day also showed a slight reduction in bodyweight gain but this was confined to Week 2 only.
No adverse effect on bodyweight development was detected for the male treatment groups or for females treated with 15 mg/kg/day.
Food Consumption: A reduction in dietary intake and food efficiency was detected for females treated with 1000 mg/kg/day during the first two weeks of the study. Food efficiency was slightly reduced for 150 mg/kg/day females but this was confined to Week 2 only.
No such effects were detected for the male treatment groups or for animals of either sex treated with 15 mg/kg/day.
Water Consumption: No intergroup differences were detected.
Haematology: Slight reductions in haemoglobin, erythrocyte count and haematocrit were detected for animals of either sex at 1000 mg/kg/day but statistical significance was not achieved.
No such effects were detected for animals of either sex treated with 150 or 15 mg/kg/day.
Blood Chemistry: Animals of either sex from all treatment groups showed an increase in plasma bilirubin, increasing in a dose-related response.
No other treatment-related effects were detected.
Organ Weights: Animals of either sex treated with 1000 mg/kg/day showed a statistically significant increase in liver weight, relative to bodyweight, compared with controls. Relative liver weight was also elevated for animals of either sex treated with 150 mg/kg/day but statistical significance was not achieved. Females treated with 1000 mg/kg/day showed an elevated relative spleen weight whilst absolute and relative adrenal weight was increased for this sex at both 1000 and 150 mg/kg/day.
No treatment-related organ weight changes were detected at 15 mg/kg/day.
Necropsy: No treatment-related macroscopic abnormalities were detected.
Histopathology: Histopathological evaluation revealed treatment-related liver changes. Centrilobular hepatocyte enlargement was observed in relation to treatment for animals of either sex treated with 1000 or 150 mg/kg/day, the effect extending to three 15 mg/kg/day males.
Hepatocyte enlargement is commonly observed in the rodent liver following the administration of xenobiotics and, in the absence of associated inflammatory or degenerative changes, it is generally considered to be adaptive in nature.
Conclusion: Oral administration of the test material, APAN, to rats for a period of twenty-eight consecutive days at dose levels of up to 1000 mg/kg/day resulted in treatment-related effects at all dose levels. A "No Observed Effect Level" (NOEL) has, therefore, not been achieved.
The treatment-related changes detected at 150 or 15 mg/kg/day were minimal and, in isolation, were considered not to represent serious damage to health, as defined by the criteria given in the EC labelling guide of Commission Directive 93/21/EEC.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.